Up to 23% of invasive breast cancers in the U.S. have mixed hormone receptor status. In other words, the tumors are classified as either estrogen receptor positive and progesterone receptor negative (ER+/PR-) or estrogen receptor negative and progesterone receptor positive (ER-/PR+). Women with ER+/PR- breast cancer are more likely to be postmenopausal, whereas those with ER-/PR+ breast cancer are more likely to be premenopausal. Endocrine treatments such as tamoxifen are used to treat both of these types, although they tend to be less effective for ER-/PR+ tumors.

Below we provide links to some of the best recent studies concerning mixed hormone receptor breast cancer prognosis and survival statistics. We are grouping these two types together not because they are very similar, but because research that mentions these types is rare and often incorporates both types.

Specific statistics concerning survival, which varies depending on numerous factors, can be found in the studies below. Please also see our articles on what to eat if you have ER+/PR- or ER-/PR+ breast cancer.